Golden Helix Receives NIH-SBIR Phase 2 Grant 2R44 GM125432-02

Integrating CNV analysis into a NextGen sequencing clinical analytics platform
 
 
Spread the Word
Listed Under

Tags:
* Genetics
* Biotech
* Next-gen Sequencing

Industry:
* Biotech

Location:
* Bozeman - Montana - US

Subject:
* Awards

BOZEMAN, Mont. - Sept. 17, 2018 - PRLog -- Golden Helix, Inc., an industry-leading genomic analytics company that specializes in clinical Next-Gen Sequencing analysis software, has announced today that the National Institutes of Health awarded them a Phase 2 SBIR Grant 2R44 GM125432-02 "Integrating CNV analysis into a NextGen sequencing clinical analytics platform".

This grant was awarded to develop and refine algorithms and applications to detect copy number variants (CNVs) and other structural variations in Next-Gen Sequencing. Also, it allows us to spearhead further development in combining these types of mutations with clinical interpretation workflows. "The NIH has been a terrific partner and supporter of our company," states Dr. Andreas Scherer President, and CEO of Golden Helix, Inc. "With the help of the approved funds, we will be able to take calculated risks pushing the currently existing boundaries of the clinical interpretation of Next-Gen Sequencing to the next level. The commitment of this grant gives us the ability to focus the next two years on advancements in this area. As the Principal Investigator of this grant, I want to express my utmost gratitude for this funding."

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. Their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from NGS sequencers and microarrays. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.

Contact
Delaina Hawkins, Marketing Manager
***@goldenhelix.com
End
Email:***@goldenhelix.com Email Verified
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Golden Helix, Inc. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share